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ResponseAbstract Background: The high failure rate in phase III oncology trials is partly because the
signal obtained from phase II trials is often weak. Several papers have considered the appro-
priateness of various phase II end-points for individual trials, but there has not been a system-
atic comparison using simulated data to determine which end-point should be used in which
situation.
Methods: In this paper we carry out simulation studies to compare the power of several
Response Evaluation Criteria in Solid Tumours (RECIST) response-based end-points for
one-arm and two-arm trials, together with progression-free survival (PFS) and testing the
tumour-shrinkage directly for two-arm trials. We consider six scenarios: (1) short-term cyto-
toxic therapy; (2) continuous cytotoxic therapy; (3 + 4) cytostatic therapy; (5 + 6) delayed
tumour-shrinkage effect (seen in some immunotherapies). We also consider measurement
error in the assessment of tumour size.
Results: Measurement error affects the type-I error rate and power of single-arm trials, and
the power of two-arm trials. Generally no single end-point performed well in all scenarios.
Best observed response rate, PFS and directly testing the tumour-shrinkages performed best
for a number of scenarios. PFS performed very poorly when the effect of the treatment was
short-lived. In scenario 6, where the delay in effect was long, no end-point performed well.
Conclusions: A clinician setting up a phase II trial should consider the likely mechanism of
action the drug will have and choose an end-point that provides high power for that scenario.
Testing the difference in tumour-shrinkage is often powerful. Alternative end-points are
required for therapies with a long delayed effect.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY
license (http://creativecommons.org/licenses/by/4.0/).el.: +44
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The strength of signal obtained in phase II oncology
trials is often low and this partly accounts for the worry-
ingly high failure rate of phase III oncology trials [1,2].
The gold-standard end-point in most tumour types is
overall survival (OS). However OS events generally
accrue too slowly to be used as the primary end-point
in a phase II trial. OS is also aﬀected by treatment cross-
over upon disease progression [3] In solid tumours,
phase II end-points are generally based on the
Response Evaluation Criteria in Solid Tumours
(RECIST) [4]. RECIST categorises each patient by the
eﬀect of the treatment on their tumour lesions. At each
time the tumour is measured, the patient is categorised
as having a complete response (CR), partial response
(PR), stable disease (SD) or progressive disease (PD).
There are two main types of end-points based on
RECIST: binary and time-to-event. Binary end-points
include the response rate (RR), the proportion of
patients whose tumour exhibits a PR or CR, and the dis-
ease control rate (DCR), the proportion of patients
whose tumour exhibits SD, PR or CR. Time-to-event
end-points include progression-free-survival (PFS) and
time-to-progression (TTP): the former measures time
to progression or death and the latter treats death as a
censoring event. RR is considered suitable for cytotoxic
drugs but less suitable for cytostatic agents [5,6]. PFS is
said to be more informative in this case [7]. Various cri-
tiques have been made of PFS [8–10], although many
criticisms also apply to RR and DCR.
The binary end-points can be further divided into
ﬁxed (also known as landmark) or best observed. In
ﬁxed analyses the RECIST categorisation at a ﬁxed time
after treatment commences is used as the end-point. In
assessing best observed response, each patient is fol-
lowed up until the end of treatment, and most favour-
able observed RECIST categorisation is used as the
end-point. Intuitively, best observed response might be
thought to be more eﬃcient as it makes use of patient
measurements taken at all timepoints. However, in col-
orectal and lung cancer trials, ﬁxed analyses were more
informative for long-term survival than best observed
response [11].
Some previous literature has compared various phase
II end-points, e.g. [11–15]. However, these studies have
been based on a small number of trials, and apply only
to speciﬁc treatments and tumour types. The literature
currently lacks a study that investigates which factors
aﬀect the power of diﬀerent end-points. In this paper
we carry out simulation studies comparing the
RECIST-based end-points in terms of power of the
phase II trial. We also consider the approach of testing
the tumour shrinkage directly [16,17]. This will mean the
most suitable phase II end-point can be chosen based onthe hypothesised mechanism of treatment on OS. We
consider both one-arm and randomised trials. For
one-arm trials we only consider response-based end-
points as the other two methods are not recommended
[7,16]. An important contribution of this paper is an
investigation of the eﬀect that measurement error, which
can be large [18], has on trials using the diﬀerent end-
points.2. Methods
2.1. Notation
For a one-arm trial testing the response-rate (how-
ever response is deﬁned) of the experimental treatment,
the true unknown response rate is denoted as p. The null
hypothesis tested is:
H 0 : p 6 p0 ð1Þ
At the end of the trial, the null hypothesis is rejected
if the number of responders is above a critical value,
chosen so that the type-I error rate of the trial (the
probability of rejecting H0 when p = p0) is equal to some
level, often 5% or 10%. The sample size is chosen so that
the power to reject H0 exceeds some level such as 80% or
90% when the true value of p is equal to a clinically rele-
vant eﬀect, p1.
A randomised trial tests the diﬀerence in eﬀectiveness
between an experimental treatment and a control treat-
ment. For response-based end-points, we denote the true
response rates of the control and experimental treat-
ments as p0 and p1 respectively. We formulate the null
hypothesis in terms of the odds-ratio (OR), which is:
OR ¼
p1
1p1
 
p0
1p0
 
:
ð2Þ
The null hypothesis is:
H 0 : OR 6 1 ð3Þ
In this case, H0 is rejected if the 95% conﬁdence inter-
val for OR does not include 1, giving a two-sided 5% sig-
niﬁcance level.
For PFS, we consider the null hypothesis being in
terms of the hazard ratio (HR), the ratio of the hazard
in the experimental arm to the hazard in the control
arm. We assume proportional hazards, i.e. HR is con-
stant over time. The null hypothesis to be tested would
be:
H 0 : HRP 1: ð4Þ
In this case, H0 can be tested using the log-rank test,
or using a Cox proportional-hazards model. We use a
Cox model and reject H0 if the p-value for the treatment
eﬀect is below 0.05.
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In order to compare the performance of the diﬀerent
end-points under diﬀerent scenarios with known proper-
ties, we used simulation studies. Each scenario repre-
sents a diﬀerent mechanism of action that a new
treatment may have. In order to better understand
which situations favour which end-point, we simulated
separately the size of target tumour lesions for each
patient at each visit and also whether they progressed
for a non-growth reason (for example due to new
lesions, or an unacceptable increase in non-target
tumour lesions).
We provide a brief, less technical, overview of how
the data were simulated. A full technical description is
given in the supplementary material.
The target tumour lesion data were simulated assum-
ing that the log tumour-size ratio [19] is normally dis-
tributed. The log tumour-size ratio at a follow-up time
for a patient with total length of lesions Xcm and pre-
vious observed length of lesions Ycm is:
log
X
Y
 
ð5Þ
For each patient, a baseline target lesion size is simu-
lated from a uniform distribution between 1 and 10 cm.
The log tumour-size ratio between two consecutive time-
points is simulated from a normal distribution. The
mean of this normal distribution is allowed to be diﬀer-
ent for each follow-up time, depending on the scenario.
Measurement error is simulated to be normally dis-
tributed on the log-scale, with zero mean and a speciﬁed
variance. As the variance increases, the potential range
of measurement error increases. Further detail is pro-
vided in the supplementary material.Table 1
Description of the six simulation scenarios.
Scenario Description
1 For the ﬁrst two treatment intervals, patients who are given th
average shrinkage) than patients given the control treatment
control treatment for subsequent treatment intervals. There is
arms. This represents a cytotoxic drug that is given for a ﬁxed
limited time
2 Patients given the experimental treatment experience a lower
set of follow-up times. The relative improvement remains con
non-growth progressions between arms. This represents a cyto
throughout the time it is given
3 Patients given the experimental treatment have the same ave
experimental treatment results in a lower probability of non-g
that is given until progression of the patient
4 A combination of scenarios 2 and 3 – the experimental treatm
probability of non-growth progressions
5 Patients given the experimental treatment have a lower avera
follow-up time onward. There is no diﬀerence in the average
diﬀerence in the probability of non-growth progressions betw
immunotherapy
6 As in scenario 5, but the delay is longer so that the treatmenOnce the true and observed tumour size at each time
are simulated, the time (if any) at which the patient
experienced a progression for non-growth reasons (i.e.
any reason other than an increase in the target lesion
size) was simulated. This was simulated using a logistic
regression, where the probability of progressing due to
non-growth reasons at each timepoint, is speciﬁed.
Parameters that determined mean tumour shrinkage
and probability of progressing for non-growth reasons
were varied between the two treatments in the case of
randomised trials. The type-I error rate was estimated
by simulating data with no diﬀerence in the mean log
tumour-size ratio or probability of non-growth failure
between the experimental treatment and control treat-
ment (for two-arm studies) or historical control (for
one-arm studies).
For single-arm trials, a sample size of 30 was used;
for two-arm trials, 150 (75 per arm) was used. These
were chosen to represent typical sample sizes seen in
practice. For each simulation, 50,000 trial replicates
were used.
2.3. Response assessment
Given a patient’s simulated target lesion size and pro-
gression for non-growth reasons, the estimate of beneﬁt
as assessed by each of the diﬀerent end-points can be cal-
culated. For the two ﬁxed response end-points (DCR
and RR), we assume that the RECIST classiﬁcation at
the second follow-up timepoint is used to classify the
treatment as having succeeded or failed, with the treat-
ment also counted as failed if the patient’s tumour pro-
gressed at the ﬁrst follow-up time point for other
reasons. For the two best observed response end-points,
the time of progression was calculated for each patient –e experimental treatment experience a lower average growth (or higher
. The experimental treatment provides the same average growth as the
no diﬀerence in the probability of non-growth progressions between the
period or a drug that is given until progression but is eﬀective only for a
average growth than patients given the control treatment for the entire
stant throughout the trial. There is no diﬀerence in the probability of
toxic drug that is given until progression of the patient and is eﬀective
rage growth in tumour size as those given the control treatment. The
rowth progressions at each timepoint. This represents a cytostatic drug
ent both reduces the average growth of target lesions and reduces the
ge growth than patients given the control treatment from the second
growth between baseline and the ﬁrst follow-up time, and there is no
een arms. This represents a drug that has a delayed eﬀect, such as an
t only has eﬀect from the fourth follow-up time onward
Fig. 1. Power of the four response-based end-points for six diﬀerent scenarios in the one-arm trial setting. Measurement error variance is set to 0.
Mean tumour shrinkage is described further in the supplementary material – negative values indicate average shrinkage in the tumour size. The
failure intercept parameter in scenario 3 is the parameter that determines the probability of progressing for a non-growth reason. More highly
negative values mean lower probabilities of progressing for non-growth reasons.
J.M.S. Wason et al. / European Journal of Cancer 51 (2015) 984–992 987
Fig. 2. Power of the four response-based end-points for six diﬀerent scenarios as the measurement error varies in the one-arm trial setting. For
scenarios 1, 2, 5 and 6 the mean tumour shrinkage is set to 0.15. For scenario 3, the failure intercept parameter is set to 3. For scenario 4, the
failure intercept parameter is set to 2.25 and the mean tumour shrinkage is set to 0.015.
988 J.M.S. Wason et al. / European Journal of Cancer 51 (2015) 984–992
J.M.S. Wason et al. / European Journal of Cancer 51 (2015) 984–992 989this is the time that either the target lesion size was more
than 20% increased compared to the nadir (i.e. the
smallest size it had been so far) or a non-growth progres-
sion occurred. Each visit up to progression was classiﬁed
according to the RECIST criteria. The most recent
RECIST guidelines [4] state that for single-arm trials,
the best observed response requires conﬁrmation.
Although conﬁrmation is not stated to be required for
two-arm trials, for simplicity we used the same deﬁnition
in all cases. Thus, if two subsequent observations before
progression were PR or CR (for RR) or SD, PR or CR
(for DCR), the treatment was classiﬁed as a success,
otherwise as a failure.
For PFS, the end-point was the time at which a
patient progressed for any reason. If the patient’s
tumour did not progress, in the follow-up time, then
they were censored at their ﬁnal observation time.
We also use the method of testing the diﬀerence in
tumour shrinkage directly [16], which is done at the sec-
ond time-point. This is described further in the supple-
mentary material.Table 2
Type-I error rate of the end-points as measurement error varies.
End-point Type-I error rate
No
measurement
error
Medium
measurement
error
(measurement
error
standard
deviation set
to 0.1)
High
measurement
error
(measurement
error
standard
deviation
set to 0.25)
Single-arm trials
Disease control
rate (DCR)
ﬁxed
0.039 0.038 0.043
Response rate
(RR) ﬁxed
0.043 0.076 0.295
DCR best
observed
0.041 0.043 0.092
RR best observed 0.031 0.034 0.091
Two-arm trials
DCR ﬁxed 0.047 0.047 0.050
RR ﬁxed 0.034 0.035 0.042
RR best observed 0.036 0.035 0.038
PFS 0.048 0.048 0.045
Karrison 0.050 0.049 0.0513. Results
3.1. Single-arm studies
Six main scenarios are described in Table 1, with
more technical details in supplementary material. In all
cases, baseline measurements and six follow-up times
were considered. In the ﬁrst scenario the experimental
treatment provides a beneﬁt in terms of tumour shrink-
age for the ﬁrst two follow-up times; the second is simi-
lar except the beneﬁt is across all follow-up times; in the
third, the experimental treatment provides a beneﬁt by
reducing the probability of non-growth progression;
the fourth is a mixture of the second and third; in the
ﬁfth scenario, the experimental treatment provides a
beneﬁt in mean tumour shrinkage from the second fol-
low-up time onward; the sixth scenario is similar to
the ﬁfth scenario but from the fourth follow-up time.
Fig. 1 shows the power of the four single-arm phase
II end-points in the six diﬀerent scenarios without mea-
surement error. In all cases, 30 patients were simulated,
and there was assumed to be no measurement error. In
scenario 1 (Fig. 1a), the two RR end-points perform
markedly better than the two DCR end-points.
Assessing response at a ﬁxed time after treatment was
more powerful than assessing the best observed
response. Scenario 2 (Fig. 1b) shows that for RR, the
best observed response is more powerful. The relative
performance of the two DCR end-points remains the
same which appears counterintuitive. However both
DCR end-points eﬀectively only use the ﬁrst two non-
baseline measurements – in the best observed DCR case,
if the one of the ﬁrst follow-up observations is a progres-
sion, then the treatment is a failure, otherwise it is asuccess. In scenario 3, the two DCR end-points are the
most powerful, with ﬁxed considerably more powerful
than best observed. In scenario 4 the pattern is the same
as in scenario 2 but with less of a gap between the RR
and DCR end-points. In scenarios 5 and 6, the power
tends to be lower than scenario 2. For scenario 6, the
best observed RR only reaches 15% power when the
mean tumour shrinkage is high; the other end-points
have no power as they are based on the ﬁrst two fol-
low-up times, in which there is no eﬀect of the experi-
mental treatment.
Fig. 2 shows the eﬀect on the power when there is
measurement error. The measurement error standard
deviation (see supplementary methods for more details)
is varied between 0 and 0.25, corresponding to no and
extremely high measurement error respectively.
Generally the best observed RR end-point is the least
aﬀected across the diﬀerent scenarios. The two DCR
end-points generally lose power as the measurement
error increases. The power of the ﬁxed RR end-point
increases as the measurement error increases. This is
partly explained by the type-I error rate. Table 2 shows
this (for all scenarios) for three diﬀerent measurement
error levels. When there is no measurement error, all
error rates are slightly lower than the 5% level on aver-
age. When there is a medium amount of measurement
error, the ﬁxed RR end-point has the highest type-I
error rate (7.6%). All other end-points appear to control
the rate well. When there is an extremely high measure-
ment error, the type-I error rate of the ﬁxed DCR end-
point is about right, but the others are inﬂated, particu-
larly the ﬁxed RR end-point.
Fig. 3. Power of ﬁxed disease control rate (DCR), ﬁxed response rate (RR), best observedRR, progression-free survival (PFS) andKarrison’smethod
in the two-arm trial setting. Measurement error variance is set to 0. Mean tumour shrinkage is described further in the supplementary material –
negative values indicate average shrinkage in the tumour size. The failure intercept parameter in scenario 3 is the parameter that determines the
probability of progressing for a non-growth reason. More highly negative values mean lower probabilities of progressing for non-growth reasons.
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Fig. 3 shows the comparison of power between RR
ﬁxed, RR best observed, DCR ﬁxed, PFS and
Karrison’s method for two-arm trials. In all scenarios,
75 patients per arm were simulated. No single end-point
performs well in all scenarios. PFS performs well in sce-
narios 2, 3, 4 and 5 (i.e. when there is a sustained eﬀect
of the treatment). Best observed RR performs at least
moderately well in all scenarios other than 3, and is best
in 2 and 5. Karrison’s method performs best in scenario
3 and well across all scenarios except 6. Fixed RR per-
forms best in 1, but not well in others. Fixed DCR is
never best but performs moderately well in 1, 3 and 4.
Scenario 6 again has low power for all end-points.
Supplementary Fig. 1 shows the power of the four
end-points when the measurement error standard devia-
tion is changed. Increased measurement error aﬀects
each end-point fairly equally. Table 2 shows the type-I
error rate is well controlled in all cases.4. Discussion
We have shown through simulation studies that the
power of the diﬀerent end-points depends on the sce-
nario and no end-point performs well in all cases.
End-points based on using all follow-up times (best
observed RR and PFS) perform better when the treat-
ment’s eﬀect persists until progression. If the treatment
only provides a beneﬁt for a limited amount of time,
the ﬁxed-time end-points are generally more powerful.
We have also shown that measurement error aﬀects
the type-I error rate of single-arm trials, but not two-
arm trials. Single-arm trials will also be aﬀected by vari-
ability in the estimated historical control response rates
[20].
Two scenarios represented a treatment that provides
a delayed eﬀect. This is of increasing interest for
immunotherapies. In the case of a long delay, none of
the phase II end-points we examined had much power.
This is because by the time the treatment eﬀect is
observed, some or most patients have already pro-
gressed. Response criteria for immunotherapies have
been proposed [21], and assessment of these would be
of interest for future work.
We have only considered RECIST-based end-points
as they are the most frequently used in solid tumour
phase II trials. However future work could consider
novel end-points such as early tumour shrinkage [22],
time to tumour growth [23], especially for scenarios,
such as a delayed eﬀect, where RECIST-based end-
points performed poorly. Novel methods for improving
existing end-points could also be compared [24,25].
A relevant question is how well the diﬀerent end-
points do in predicting the treatment’s success at phase
III. A clinician who is interested in running a phase IItrial should consider how the treatment is likely to bring
about improved long-term survival (if that is the phase
III end-point to be considered). Pre-clinical information
and trials from drugs in the same class could be used to
determine if the eﬀect is likely to be throughout treat-
ment, for a limited time or delayed. The results here then
can be used to choose a powerful and robust end-point.
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